drugset / Trial / NCT00005808

Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00005808

Phase 1 Terminated 54 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Phase I trial to study the effectiveness of photodynamic therapy with lutetium texaphyrin in treating patients who have cervical intraepithelial neoplasia. Photodynamic therapy uses light and drugs such as lutetium texaphyrin that make abnormal cells more sensitive to light and may kill abnormal cells in the cervix and prevent the development of cervical cancer

Timeline

Start
2000-12
Primary completion
2004-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject motexafin lutetium Small molecule Intravenous